ArticleNature communications2021
Universal toxin-based selection for precise genome engineering in human cells.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- High-diversity base mutagenesis via simultaneous adenine, cytosine and guanine editing.Nature communications · 2026Article
- Article
- Search-and-remove genome editing allows selection of cells by DNA sequence.Nature communications · 2025Article
- HSP90 buffers deleterious genetic variations in BRCA1.Molecular cell · 2025Article
- Activity-based selection for enhanced base editor mutational scanning.Nature genetics · 2025Article
- Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy.Nature communications · 2025Article
- Homozygous editing of multiple genes for accelerated generation of xenotransplantation pigs.Genome research · 2025Article
- AnBioengineering & translational medicine · 2025Article
- High-throughput screening of human genetic variants by pooled prime editing.Cell genomics · 2025Article
- Repair Drive improves gene editing in the liver.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Optimized prime editing of the Alzheimer's disease-associated APOE4 mutation.Stem cell reports · 2025Article
- Base editors in zebrafish: a new era for functional genomics and disease modeling.Frontiers in genome editing · 2025Review
- Engineered PsCas9 enables therapeutic genome editing in mouse liver with lipid nanoparticles.Nature communications · 2024Article
- High-Efficiency Multiplexed Cytosine Base Editors for Natural Product Synthesis inACS synthetic biology · 2023Article
- A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo.Nature communications · 2023Article
- Precise mutagenesis in zebrafish using cytosine base editors.Nature protocols · 2023Review
- Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing.Nature communications · 2023Article
- Enrichment strategies to enhance genome editing.Journal of biomedical science · 2023Review
- Transition Substitution of Desired Bases in Human Pluripotent Stem Cells with Base Editors: A Step-by-Step Guide.International journal of stem cells · 2023Article
- TLCD1 and TLCD2 regulate cellular phosphatidylethanolamine composition and promote the progression of non-alcoholic steatohepatitis.Nature communications · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
22 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prokaryotic restriction enzymes, recombinases and Cas proteins are powerful DNA engineering and genome editing tools. However, in many primary cell types, the efficiency of genome editing remains low, impeding the development of gene- and cell-based therapeutic applications. A safe strategy for robust and efficient enrichment of precisely genetically engineered cells is urgently required. Here, we screen for mutations in the receptor for Diphtheria Toxin (DT) which protect human cells from DT. Selection for cells with an edited DT receptor variant enriches for simultaneously introduced, precisely targeted gene modifications at a second independent locus, such as nucleotide substitutions and DNA insertions. Our method enables the rapid generation of a homogenous cell population with bi-allelic integration of a DNA cassette at the selection locus, without clonal isolation. Toxin-based selection works in both cancer-transformed and non-transformed cells, including human induced pluripotent stem cells and human primary T-lymphocytes, as well as it is applicable also in vivo, in mice with humanized liver. This work represents a flexible, precise, and efficient selection strategy to engineer cells using CRISPR-Cas and base editing systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.